Call for Science

Submitting an abstract, case report, or late-breaking science to SCAI's Scientific Sessions allows you to share your work with our global community. Share your experience, knowledge, latest clinical data, and medical advances with your peers and contribute to improving practice and the patient experience.

Submissions are welcomed from physicians, cardiovascular professionals, hospital administrators, academics, and industry professionals from around the world.

 

abstract icon

Abstracts

Submissions will be considered for the poster hall or oral presentation. All accepted abstracts will be included in a special JSCAI issue. 

  • Submission is FREE!
  • Accepted presenters will be asked to prepare a printed poster or prepare an oral presentation.   
  • All accepted presenters will be asked to upload an electronic version of their abstract in advance of the meeting. 
  • All accepted presenters receive non-transferable complimentary registration. 

Deadline: January 23, 2023

Case Submissions

Submissions must include a PowerPoint file and are considered for oral presentation.

  • Submission is FREE!
  • Accepted case presenters will be asked to prepare an oral presentation to be presented in one of the track sessions. 
  • All accepted presenters will be asked to upload their slides in advance of the meeting. 
  • All accepted presenters receive non-transferable complimentary registration.

Deadline: January 23, 2023

clinical case submission icon
late breaking icon

Late Breaking Science

The Program Committee is looking for late-breaking clinical science, follow-up data from major randomized trials, single or multicenter registries, and first-in-man experiences with novel devices or drugs. Submissions will be considered for oral presentation in a featured session.

  • Submission is FREE!
  • All accepted abstracts will be given the opportunity for simultaneous publication in SCAI's official journal, JSCAI.
  • All accepted presenters receive non-transferable complimentary registration.

Call Opens: January 24, 2023

Deadline: February 22, 2023

Click Here for Abstract Guidelines
  1. Abstracts can include a maximum of three image uploads in the following accepted file formats: JPG, JPEG, PNG, and GIF. Abstracts must contain the following four sections, which must not exceed a combined total of 1,900 characters: Background, Methods, Results, and Conclusions. Please also note that each image upload counts as 500 characters. 
  2. Abstracts that have been previously published or presented will NOT be eligible for presentation at SCAI. If your abstract is accepted for presentation at another meeting or published prior to SCAI 202 Scientific Sessions, you must notify SCAI immediately to withdraw your abstract. 
  3. Case studies will NOT be accepted or considered for abstract poster presentation at the SCAI 2023 Scientific Sessions. SCAI has a separate call for cases where you should submit your interesting cases and case reports. 
  4. Investigators should not submit the same research; applications that appear to be replicate versions of a single study will be rejected. 
  5. The SCAI Program Committee endorses the position of the American Association for the Advancement for Science (AAAS) in requiring assurances of the responsible use of animals in research. All submissions for consideration must follow these guidelines. 
  6. Abstract submissions must fit into one of the following categories:
    • Acute Coronary Syndromes and Myocardial Infarction (MI) 
    • Adult Congenital 
    • Angiogenesis, Myogenesis, Cell Therapy, and Gene Therapy 
    • Cardiogenic Shock and Hemodynamic Support 
    • Carotid Interventions 
    • Complex Percutaneous Coronary Intervention (PCI) and Restenosis (Excluding Left Main and Multivessel Intervention) 
    • Imaging: Computerized Tomography (CT), Magnetic Resonance Imaging (MRI), and Noninvasive Imaging 
    • Intervention for Stable Ischemic Heart Disease 
    • Intravascular Imaging (Intravascular Ultrasound [IVUS]/Optical Coherence Topography [OCT]/Near Infrared [NIR]/Other) and Physiology (Fractional Flow Reserve [FFR]/Instantaneous Wave-Free Ratio [iFR]/Index of Microcirculatory Resistance [IMR]/Other) 
    • Left Main and Multivessel Intervention
    • Miscellaneous 
    • Other Endovascular Interventions (Including Renal Denervation and Abdominal Aortic Aneurysm [AAA]) 
    • Pediatric 
    • Peripheral Artery Disease (PAD) and Critical Limb Ischemia (CLI) 
    • Pharmacotherapy 
    • Pulmonary Embolism 
    • Quality Improvement 
    • Structural Heart Disease (Excluding Valvular Interventions) 
    • Thrombectomy and Vulnerable Plaque 
    • Transcatheter Aortic Valve Replacement (TAVR) 
    • Valvular Interventions (Excluding TAVR) 
    • Vascular Access and Arterial Closure Devices 
    • Venous Disease (Including Deep Vein Thrombosis [DVT], Insufficiency) 
  7. Each presenting author must comply with the SCAI Disclosure Policy and must provide the following: indication of the relationship, the associated commercial entity, and the level. All presenters at SCAI's Annual Scientific Sessions must display a slide at the beginning of their presentation indicating disclosure information, as applicable, or that they have nothing to disclose. 
  8. There is no limit on the number of authors for abstract submissions. 
  9. All revisions must be made by the abstract submission deadline. 
  10. The submitter acts on behalf of all co-authors and in submitting an abstract/late-breaking clinical science, transfers to SCAI the copyright and all other rights in the material comprising the application if the application is accepted. Co-authors reserve the following: 
  11. All proprietary rights other than copyright, such as patent rights 
  12. The right to use all or part of the application in future works of their own. SCAI and its new official journal, JSCAI, as holder of the copyright on the accepted application, reserves all rights of reproduction, distribution, performance, display, and the right to create derivative works in both print and digital formats. 
  13. Abstract acceptance notifications will be emailed to the addresses provided for the presenting authors, along with presentation guidelines. 
  14. Requests to withdraw an abstract must be submitted in writing to abstracts@scai.org by March 1, 2023.  
  15. SCAI promotes abstracts, late-breaking clinical science, research, and presentations to online, print, and broadcast media on behalf of Scientific Sessions. 
  16. Embargoed content: All authors, presenters, company sponsors, attendees, journalists, and/or anyone with knowledge of embargoed content must comply with SCAI embargo policies, which state that scientific study results presented during Scientific Sessions must not be released publicly prior to the embargo date and time. If the media contacts authors directly, authors, presenters, and/or company sponsors must first seek SCAI approval for information to be shared with the understanding that it is under embargo. Responsibility for information shared in this manner rests solely with the disclosing authors, presenters, and/or company sponsors. SCAI leadership, press staff, and meeting co-chairs will be available to work with the disclosing party to develop an acceptable release of the required information if specific disclosures (e.g., Securities and Exchange Commission requirements) must be met or in the case of a public health concern. The only exception to the above-mentioned embargo rules are closed investigatomeetings for participants in the trial. The SCAI Program Committee may ask you to supply investigator meeting date/time/location information if your submission is accepted. 

Specific Embargo Dates and Times: 

*Oral Presentations: Abstracts selected for oral presentation are embargoed from the time of submission until conclusion of their presentations at Scientific Sessions. 

*Poster Presentations: Abstracts selected for poster presentation are embargoed from the time of submission until the start of Scientific Sessions. 

*Abstracts included in SCAI’s official Press Program are embargoed from the time of submission until conclusion of the press conference in which the research is presented or until conclusion of the presentation at the Scientific Sessions, whichever is first. Authors will be notified directly if their study has been selected for the Press Program, and the specific embargo details for their study will be provided.

Abstract Availability: Embargoed text of abstracts, not in the Press Program, will be made available online two weeks prior to the start of Scientific Sessions. Note: The abstract embargo still applies; however, abstracts are made available to attendees to assist in creating their itineraries for the meeting.

 

Click Here for Case Guidelines
  1. A case submission must include a case report and a PowerPoint presentation. The case report must be limited to 500 words (not including headers) and must contain the following sections: Title, Introduction, Clinical Case, and Discussion. 
  2. The SCAI Program Committee endorses the position of the American Association for the Advancement for Science (AAAS) in requiring assurances of the responsible use of animals in research. All submissions for consideration must follow these guidelines. 
  3. Case submissions must fit into one of the following categories: 
    • Acute Coronary Syndromes and Myocardial Infarction (MI) 
    • Adult Congenital 
    • Angiogenesis, Myogenesis, Cell Therapy, and Gene Therapy 
    • Cardiogenic Shock and Hemodynamic Support 
    • Carotid Interventions 
    • Complex Percutaneous Coronary Intervention (PCI) and Restenosis (Excluding Left Main and Multivessel Intervention) 
    • Imaging: Computerized Tomography (CT), Magnetic Resonance Imaging (MR), and Noninvasive Imaging 
    • Intervention for Stable Ischemic Heart Disease 
    • Intravascular Imaging (Intravascular Ultrasound [IVUS]/Optical Coherence Topography [OCT]/Near Infrared [NIR]/Other) and Physiology (Fractional Flow Reserve [FFR]/Instantaneous Wave-Free Ratio [iFR]/Index of Microcirculatory Resistance [IMR]/Other) 
    • Left Main and Multivessel Intervention 
    • Miscellaneous 
    • Other Endovascular Interventions (Including Renal Denervation and Abdominal Aortic Aneurysm [AAA]) 
    • Pediatric 
    • Peripheral Artery Disease (PAD) and Critical Limb Ischemia (CLI) 
    • Pharmacotherapy 
    • Pulmonary Embolism 
    • Quality Improvement 
    • Structural Heart Disease (Excluding Valvular Interventions) 
    • Thrombectomy and Vulnerable Plaque 
    • Transcatheter Aortic Valve Replacement (TAVR) 
    • Valvular Interventions (Excluding TAVR) 
    • Vascular Access and Arterial Closure Devices 
    • Venous Disease (Including Deep Vein Thrombosis [DVT], Insufficiency) 
  4. Each presenting author must comply with the SCAI Disclosure Policy and must provide the following: indication of the relationship, the associated commercial entity, and the level of support. All presenters at SCAI's Annual Scientific Sessions must display a slide at the beginning of their presentation indicating disclosure information, as applicable, or that they have nothing to disclose. 
  5. There is no limit on the number of authors for case submissions. 
  6. All revisions must be made by the case submission deadline. 
  7. The submitter acts on behalf of all co-authors and in submitting a case, transfers to SCAI the copyright and all other rights in the material comprising the application if the application is accepted. Co-authors reserve the following: 
  8. All proprietary rights other than copyright, such as patent rights 
  9. The right to use all or part of the application in future works of their own. SCAI and its new official journal, JSCAI, as holder of the copyright on the accepted application, reserves all rights of reproduction, distribution, performance, display, and the right to create derivative works in both print and digital formats. 

Case acceptance notifications will be emailed to the addresses provided for the presenting authors, along with presentation guidelines. 
Requests to withdraw a case must be submitted in writing to cases@scai.org by March 1, 2023. 

Abstract Presentation Guidelines

Information below pertains to only invited abstract presenters. The presenting author has been notified and informed of their assigned poster or oral presentation.

Poster Presenters

As a poster presenter you are required to prepare a printed poster and display it at your assigned time. You are also invited to prepare a PDF of your poster and  upload the PPT in the Speaker Service Center. The PPT will be available on the meeting app.  All Abstract Poster Presenters must register for the meeting, with your complimentary access code provided in your acceptance email.  Please see additional details and instructions below. 

Poster Specifications

  • Printed Posters are MANDATORY. Complimentary registration for the poster presenter is conditional on your poster being displayed during your assigned poster time. If you attend and do not display your poster you will be charged the registration fee. 
  • The allowable size of the poster is 45” wide and 45” high. You must keep your poster within these dimensions. There will be two posters on each side of a poster board.
  • It is recommended that you include your full-text abstract on the poster which includes the background, methods, results, and conclusion. 
  • Please include the title of the abstract, your name, and institution on the poster.
  • Please note that we cannot allow poster presenters to make special requests for date or time of the presentation. All presentation dates are final. 

Poster Set-up and Take-down

  • Please arrive 10-15 before your scheduled poster session time to hang your poster (see below for sessions times).
  • Please take down your poster immediately after scheduled poster session time ends.
  • DO NOT leave your poster or holder on the floor in the poster area. We cannot guarantee the security and safety of your poster. If you leave your poster on the floor unattended it may be discarded.

Oral Abstract Presenters

As an oral abstract presenter, you are required to prepare a 10 minute PPT presentation. You will present your abstract in the Exhibit Hall at the “Presentation Theater” during your assigned time. You are also invited to upload a copy of your PPT presentation in the Speaker Service Center. The PPT will be available on the meeting app. All Abstract Presenters must register for the meeting, with your complimentary access code provided in your acceptance email. 

Abstract Presentation Hours

Abstract Session times represent the times in which posters will be hung in the North Hall CD and the Presentation Theater will take place Please refer to your poster acceptance email regarding your assigned poster session and poster number or assigned speaking time. 

Poster Session Times

Session
Day
Date
Time
A Thursday May 18, 2023 9:40 - 10:30 am
B Thursday May 18, 2023 3:55 - 4:25 pm
C Friday May 19, 2023 10:30 - 11:10 am
D Friday May 19, 2023 3:00 - 3:40 pm
E Saturday May 20, 2023 10:40 - 11:20 am

 

FedEx Poster Printing

SCAI will be partnering with the FedEx Office at the Hyatt Regency Atlanta to offer a discounted printing price for posters. The size FedEx can print onsite is 42”x42” max. The link to order will be available April 25th.  

Questions?

If you have any questions or concerns, please email us at: abstracts@scai.org.  
 

Questions?

Email: abstracts@scai.org

Phone: 800-992-7224